Subscribe To
elevar therapeutics announces publication of phase 3 cares 310 study results in the lancet
In CARES 310, camrelizumab plus rivoceranib demonstrated statistically significant and clinically meaningful prolonged overall survival and progressio...
July 25, 2023, 1:39 am